IGBA Offers Input On WHO Pandemic Accord
Highlights Harmonization, IP, Regulatory Efficiency And Supply-Chain Sustainability
As the WHO seeks input on a global accord to strengthen pandemic preparedness, the IGBA has provided suggestions from the off-patent industry ahead of a key step in the drafting process later this month.
You may also be interested in...
Biogen has celebrated the approval by the US FDA of its Bio-Thera-partnered Tofidence biosimilar rival to Actemra. The firm said it was “currently evaluating the potential launch timeline.”
Fresenius Kabi and Formycon have seen their filing for an ustekinumab biosimilar rival to Stelara accepted for review by the European Medicines Agency. A filing with the US FDA is also on the way.
Ahead of the Global Generics & Biosimilars Awards, which are this year being held on Wednesday 25 October at the Hotel Porta Fira in Barcelona, we reveal our final shortlist of entrants across all 14 categories.